Freyja Healthcare, LLC announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its VereSee™ Mini Laparoscope with VisualEntry™ System. This clearance marks a significant step in the company’s mission to enhance visualization at the earliest stages of minimally invasive surgery, potentially transforming how surgeons approach laparoscopic procedures.
The VereSee system integrates a miniature 2mm laparoscope with Freyja’s VisualEntry technology, allowing surgeons to visualize anatomy during the entry process itself. Traditionally, initial abdominal access in laparoscopic surgery is performed without direct visualization, a limitation that VereSee aims to overcome. By providing sight during entry, the device offers a new approach to a critical step in surgery, which could improve safety and precision.
“FDA clearance of VereSee is an incredibly important milestone for Freyja Healthcare,” said Mike MacKinnon, CEO of Freyja Healthcare. “We believe surgeons should have the ability to see when it matters most. VereSee brings visualization to the very beginning of the procedure while also providing the functionality of a miniature laparoscope, which may enable surgeons to avoid opening an additional laparoscope for certain procedures.”
Once access is achieved, VereSee can continue to serve as the primary visualization tool, potentially eliminating the need for a separate laparoscope in some cases. This dual functionality not only simplifies the surgical workflow but also offers a practical healthcare economic model by pairing single-use entry components with reusable visualization technology.
The FDA reviewed VereSee under the 510(k) premarket notification pathway, classifying it as a Class II Endoscope and Accessories device. The clearance underscores the device’s safety and effectiveness for its intended use.
Jon I. Einarsson, MD, founder of Freyja Healthcare, emphasized the broader implications: “VereSee represents more than a new method of laparoscopic entry. It is a miniature laparoscopic visualization platform that gives surgeons the opportunity to see anatomy from the moment of entry. We believe that has the potential to fundamentally change how surgeons think about access, while continuing to advance the miniaturization of laparoscopic visualization and scope functionality.”
The ability to visualize during entry could reduce the risk of inadvertent injury to underlying structures, a concern that has driven interest in optical access techniques. By providing real-time visualization, the VereSee system may enhance patient safety and procedural outcomes.
With the FDA clearance in hand, Freyja Healthcare is set to begin the commercial introduction of VereSee, making the technology available to hospitals, ambulatory surgical centers, and surgeons performing minimally invasive procedures. The company, based in Framingham, MA, focuses on developing innovative solutions for minimally invasive surgery and women’s health, aiming to improve visualization, access, and procedural efficiency while addressing unmet needs for physicians, healthcare systems, and patients.
This approval comes at a time when the medical device industry is increasingly focused on improving surgical precision and patient outcomes. The VereSee system’s unique approach to laparoscopic entry could set a new standard, potentially influencing future developments in surgical visualization technology.
